Biopharmaceutical Third Party Logistics Market Size & Growth Forecast 2027–2036, By Segments (Supply Chain, Service Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Biopharmaceutical Third Party Logistics Market size was more than USD 161.4 billion in 2026 and is set to grow at a 6.56% CAGR between 2027 and 2036, attaining USD 304.68 billion by 2036. The industry revenue for 2027 is estimated at USD 170.31 billion.
Get more details on this report
Request Free Sample ReportBiopharmaceutical Third Party Logistics Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 45.08% share in 2026, supported by mature cold-chain infrastructure, high biopharmaceutical volumes, and demand for compliant logistics solutions.
- Asia Pacific is expected to expand at a 6.89% CAGR, fueled by increasing biopharmaceutical production, specialized supply chain adoption, and growing distribution needs.
Segment Momentum
- Non-cold Chain Logistics accounted for 75.33% of the market in 2026, supported by broader applicability, established infrastructure, simpler handling requirements, and lower operational complexity across routine distribution activities.
- Transportation is growing fastest because demand is increasing for timely, compliant, and specialized product movement, where delivery reliability, route control, and shipment condition management are critical.
Market Expansion Drivers
- Growing demand for temperature-sensitive biologics increasing reliance on specialized cold-chain logistics.
- Adoption of AI, IoT, and blockchain improving pharmaceutical supply chain transparency and monitoring.
- Expansion of gene therapies and personalized medicines driving need for precision logistics infrastructure.
Leading Market Participants
- Prominent companies in the biopharmaceutical third party logistics market include DHL Group (Germany), FedEx Corporation (United States), United Parcel Service, Inc. (United States), Kuehne + Nagel International AG (Switzerland), DB Schenker (Germany), Cencora, Inc. (United States), SF Express Co., Ltd. (China), Kerry Logistics Network Limited (Hong Kong), Agility Public Warehousing Company K.S.C.P. (Kuwait), Nippon Express Holdings, Inc. (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 161.4 billion
- 2027 Estimated Market Size: USD 170.31 billion.
- Projected Market Size: USD 304.68 billion by 2036
- Growth Forecast: 6.56% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Non-cold Chain Logistics (Supply Chain) | Warehousing and Storage (Service Type)
- Emerging Opportunity Segment: Cold Chain Logistics (Supply Chain) | Transportation (Service Type)
Market Growth Drivers and Industry Trends
Growing demand for temperature-sensitive biologics increasing reliance on specialized cold-chain logistics
The biopharmaceutical third party logistics market is being supported by the expanding use of temperature-sensitive biologics, which require controlled storage and transportation conditions to preserve product quality and therapeutic efficacy. Increasing volumes of biologic drugs, including products with stringent temperature requirements, are encouraging pharmaceutical manufacturers to rely on specialized logistics providers with validated cold-chain capabilities, temperature-controlled warehousing, real-time shipment monitoring, and specialized handling procedures. This growing operational complexity makes outsourced logistics increasingly valuable for manufacturers seeking to maintain product integrity across distribution networks while managing the requirements associated with sensitive pharmaceutical products.
Adoption of AI, IoT, and blockchain improving pharmaceutical supply chain transparency and monitoring
Adoption of digital technologies such as AI, IoT, and blockchain will propel the biopharmaceutical third party logistics market by enabling greater visibility and control across pharmaceutical supply chains. IoT-enabled sensors can continuously monitor shipment conditions, while AI can support predictive analysis, exception management, and operational decision-making, allowing logistics providers to identify potential disruptions more efficiently. Blockchain-based systems can further strengthen traceability by creating more transparent records of product movements and transactions, supporting greater accountability across complex distribution networks and helping logistics operators manage increasingly sophisticated pharmaceutical supply chain requirements.
Expansion of gene therapies and personalized medicines driving need for precision logistics infrastructure
Expansion of gene therapies and personalized medicines is creating more demanding distribution requirements, strengthening the role of precision logistics infrastructure within the biopharmaceutical third party logistics market. These therapies can involve highly specialized handling, controlled transportation conditions, strict chain-of-custody procedures, and coordinated movement between manufacturing facilities, treatment centers, and other healthcare locations. As pharmaceutical portfolios become more specialized and patient-specific, logistics providers increasingly need capabilities designed around precise shipment timing, product identification, temperature control, and secure handling throughout the distribution process.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing demand for temperature-sensitive biologics increasing reliance on specialized cold-chain logistics | 2.30% | High | North America, Europe, Asia Pacific | High | Near Term |
| Adoption of AI, IoT, and blockchain improving pharmaceutical supply chain transparency and monitoring | 1.90% | Moderate | North America, Europe | High | Mid Term |
| Expansion of gene therapies and personalized medicines driving need for precision logistics infrastructure | 1.60% | High | North America, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held a 45.08% share of the biopharmaceutical third party logistics market in 2026, supported by its established biopharmaceutical industry, sophisticated cold-chain infrastructure, and strong demand for specialized logistics services. The region benefits from stringent requirements for temperature-controlled transportation, secure product handling, and regulatory compliance, encouraging biopharmaceutical companies to rely on specialized third-party providers. Advanced distribution networks, healthcare infrastructure, and increasing adoption of technology-enabled logistics solutions further reinforce regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth as pharmaceutical manufacturing and biopharmaceutical development expand across the region. Rising healthcare demand, increasing investments in life sciences infrastructure, and the development of sophisticated pharmaceutical supply chains are creating greater requirements for reliable third-party logistics services. Improvements in cold-chain capabilities, regulatory systems, and transportation infrastructure are also supporting the movement of temperature-sensitive biologics and strengthening the region's position in the evolving biopharmaceutical logistics landscape.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Regulated Distribution ExpertiseGermany prioritizes biopharmaceutical third party logistics services that maintain product integrity through validated cold chain operations and advanced monitoring systems. Pharmaceutical companies increasingly rely on specialized logistics partners for compliant domestic and international distribution.
France 🇫🇷
Specialty Distribution SupportFrance continues strengthening biopharmaceutical third party logistics through investments in specialized storage, transport validation, and pharmaceutical handling expertise. Companies prioritize logistics providers capable of maintaining consistent product quality across healthcare distribution networks.
Italy 🇮🇹
Healthcare Supply CoordinationItaly is enhancing the biopharmaceutical third party logistics market by improving coordination between manufacturers, distributors, and healthcare facilities. Logistics providers focus on secure cold chain execution and flexible delivery models that support the handling of sensitive biopharmaceutical products.
Japan 🇯🇵
Temperature-Controlled ReliabilityJapan focuses on biopharmaceutical third party logistics solutions that ensure stable handling of high-value biologic products throughout the supply chain. Logistics providers invest in precise temperature management and traceability technologies to support pharmaceutical quality requirements.
South Korea 🇰🇷
Integrated Logistics InfrastructureSouth Korea is expanding biopharmaceutical third party logistics capabilities through modern distribution centers and digital supply chain management. Pharmaceutical companies seek logistics partners that provide responsive cold chain services and efficient inventory control for specialized therapies.
United States 🇺🇸
Cold Chain OptimizationThe U.S. biopharmaceutical third party logistics market emphasizes temperature-controlled distribution, real-time shipment visibility, and regulatory compliance. Logistics providers continue expanding specialized infrastructure to support reliable delivery of biologics, vaccines, and other sensitive pharmaceutical products.
Segment Leadership and Growth Trends
Biopharmaceutical Third Party Logistics Market Share (%), by Supply Chain, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportSupply Chain Segment Analysis: Non-cold Chain Logistics (Largest Segment) vs Cold Chain Logistics (Fastest-Growing Segment)
Non-cold chain logistics accounted for a 75.33% share of the biopharmaceutical third party logistics market in 2026, reflecting the extensive movement and storage requirements for biopharmaceutical materials that do not require controlled-temperature environments. These logistics services support distribution activities across a broad range of products and benefit from established warehousing, transportation, and inventory management networks. Increasing biopharmaceutical production and expanding distribution requirements continue to sustain demand for reliable third-party logistics capabilities.
Cold chain logistics is the fastest-growing supply chain segment, supported by the increasing importance of temperature-sensitive biologics, vaccines, and other advanced therapies. Maintaining appropriate environmental conditions throughout storage and transportation is essential for preserving product quality and stability, increasing the need for specialized logistics infrastructure and monitoring capabilities. The expansion of biologic therapies and increasingly sophisticated pharmaceutical products is therefore strengthening demand for temperature-controlled supply chain services.
Service Type Segment Analysis: Warehousing and Storage (Largest Segment) vs Transportation (Fastest-Growing Segment)
Warehousing and storage held the largest share of the biopharmaceutical third party logistics market, accounting for 45.74% in 2026. Its leading position reflects the need for secure inventory management, controlled storage environments, and reliable handling of biopharmaceutical products throughout distribution networks. As manufacturers and healthcare supply chains manage increasingly specialized products, third-party warehousing providers offer infrastructure and operational expertise that can improve inventory flexibility and distribution efficiency.
Transportation is advancing as the fastest-growing service type as biopharmaceutical supply chains become more geographically distributed and require dependable movement between manufacturing sites, storage facilities, healthcare providers, and other destinations. Specialized transportation capabilities are particularly important for products requiring strict handling, monitoring, and delivery conditions. The growing complexity of biopharmaceutical distribution is consequently increasing demand for coordinated transportation solutions that can preserve product integrity across the supply chain.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Supply Chain | Cold Chain Logistics, Non-cold Chain Logistics | Non-cold Chain Logistics | Cold Chain Logistics |
| Service Type | Transportation, Warehousing and Storage, Others | Warehousing and Storage | Transportation |
Competitive Landscape and Market Positioning
Prominent players in the biopharmaceutical third party logistics market:
1. DHL Group (Germany)
2. FedEx Corporation (United States)
3. United Parcel Service Inc. (United States)
4. Kuehne + Nagel International AG (Switzerland)
5. DB Schenker (Germany)
6. Cencora Inc. (United States)
7. SF Express Co. Ltd. (China)
8. Kerry Logistics Network Limited (Hong Kong)
9. Agility Public Warehousing Company K.S.C.P. (Kuwait)
10. Nippon Express Holdings Inc. (Japan)
The biopharmaceutical third party logistics market is increasingly focused on cold-chain optimization, compliance management, and advanced shipment visibility solutions. Growing demand for temperature-sensitive biologics and specialty therapies has encouraged investments in smart tracking technologies and automated storage systems. Regulatory requirements surrounding product integrity and traceability are also influencing competitive strategies across the logistics ecosystem.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| DHL Group (Germany) | |||||||
| FedEx Corporation (United States) | |||||||
| United Parcel Service Inc. (United States) | |||||||
| Kuehne + Nagel International AG (Switzerland) | |||||||
| DB Schenker (Germany) | |||||||
| Cencora Inc. (United States) | |||||||
| SF Express Co. Ltd. (China) | |||||||
| Kerry Logistics Network Limited (Hong Kong) | |||||||
| Agility Public Warehousing Company K.S.C.P. (Kuwait) | |||||||
| Nippon Express Holdings Inc. (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| United Parcel Service (UPS) | Oct-24 | UPS launched a new cross-docking facility in India specifically designed for healthcare logistics. The facility supports diverse temperature-controlled storage needs, including dedicated space for cold-chain pharmaceutical products (+2°C to +25°C) and ambient storage, enhancing the company’s regional freight forwarding capabilities for clinical and commercial biopharmaceutical shipments. |
| FedEx | Feb-24 | FedEx expanded its specialized logistics footprint in India through its Life Science Center. This facility provides dedicated storage and distribution infrastructure designed to meet the high-compliance requirements of clinical trial logistics, supporting both domestic Indian healthcare customers and international companies importing pharmaceutical products into the region. |
| FedEx Express | Aug-23 | FedEx Express entered a strategic collaboration with the Gyeongsangbuk-do provincial government in South Korea. The partnership aims to provide logistics support to local small and medium-sized enterprises (SMEs) looking to scale their operations in high-growth sectors, including the biopharmaceutical and semiconductor markets, by leveraging FedEx’s global transportation and supply chain infrastructure. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Biopharmaceutical Third Party Logistics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Client Type | Pharmaceutical Companies, Biotechnology Companies, Contract Research & Development Organizations (CROs), Contract Manufacturing Organizations (CMOs) |
| Product Lifecycle Stage | Clinical Development, Commercial Launch, Commercial Distribution, Post-Market & Specialty Products |
| Shipment Volume Category | Small-Volume Shipments, Medium-Volume Shipments, High-Volume Shipments |
Biopharmaceutical Third Party Logistics Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Cold Chain Logistics Capability Benchmarking |
|
| Biopharma Logistics Partner Selection Framework |
|
| Cell and Gene Therapy Logistics Outlook |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the biopharmaceutical third party logistics market?
What is the projected value of the biopharmaceutical third party logistics industry by 2036?
Why is demand increasing for specialized cold-chain logistics providers in biopharmaceutical distribution?
How are advanced digital technologies influencing third-party logistics provider selection?
Why does non-cold chain logistics hold the largest share of the biopharmaceutical third party logistics market?
Why is transportation the fastest-growing service type in the biopharmaceutical third party logistics market?
Why does North America dominate the biopharmaceutical third party logistics market?
What is driving Asia Pacific growth in biopharmaceutical third party logistics?
Which companies are driving growth in the biopharmaceutical third party logistics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization